Unscheduled Cancer Pain Admissions Costly: Close to $5 Million a Year at M.D. Anderson

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

HOUSTON-Unscheduled hospital admissions for treatment of pain represent a significant cost-$4.7 million annually in a study from The University of Texas M.D. Anderson Cancer Center.

HOUSTON-Unscheduled hospital admissions for treatment of painrepresent a significant cost-$4.7 million annually in a studyfrom The University of Texas M.D. Anderson Cancer Center.

Monica M. Larsen, BA, of the Department of Pharmacoeconomics,who presented the abstract at the 8th World Congress on Pain,said that more effective outpatient pain interventions are thekey to reducing these expensive admissions.

Ms. Larsen and her colleagues reviewed the records of all patientsadmitted through the emergency care unit over a 6-month period.

Of the 1,166 total admissions, 14% were for pain, ranking secondonly to fever (35%). The reasons for the pain admissions werepain management (60%), abdominal pain (24%), chest pain (10%),headache (5%), and back pain (1%).

The mean length of stay for pain admissions was 10.5 days, andthe mean patient charge per admission was $19,000 ($1,800 perday).

Using the hospital-specific cost-to-charge ratio of 0.74, theresearchers determined that the actual hospital cost per admissionfor pain was $14,000 ($1,300 per day). Thus, they were able topredict an annual cost of about $4.7 million for unscheduled painadmissions.

Recent Videos
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series